Sorrento Therpt (SRNE)

Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.

Sorrento Therapeutics Remains a Buy Between $6 and $6.50

By Will Ashworth, InvestorPlace Contributor Dec 7, 2020

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful.

Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics

By Chris Lau, InvestorPlace Contributor Dec 7, 2020

SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.

Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk

By Thomas Niel Dec 4, 2020

SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play.

The Shock and Awe of Sorrento Therapeutics Is Long Gone

By Chris Markoch Dec 4, 2020

Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.

Hopefuls Back Sorrento Therapeutics But Time Is a Factor

By Larry Sullivan, InvestorPlace contributor Dec 4, 2020

Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.

Sorrento Stock Doesn’t Offer Any Upside as Vaccine Frontrunners Emerge

By Faizan Farooque Dec 2, 2020

The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.

Windows of Opportunity Are Tightening for Sorrento Therapeutics

By Josh Enomoto, InvestorPlace Contributor Nov 30, 2020

Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.

Don’t Bail on Sorrento Therapeutics Stock Just Yet

By Matt McCall and the InvestorPlace Research Staff, Editor, MoneyWire Nov 30, 2020

SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.

Avoid Sorrento Therapeutics, Which Is Still Burning Cash With No End In Sight

By Mark R. Hake, CFA Nov 30, 2020

Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor Nov 24, 2020

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

Sorrento Therapeutics Hoping Better Late Than Never Works in Vaccine Competition

By Todd Shriber, InvestorPlace Contributor Nov 23, 2020

In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.